Dr. Sui has 30 years of experience in drug discovery and development. He is currently Chief Scientific Officer and Head of Preclinical Research and Development at Proteovant Therapeutics (https://proteovant.com/), a biotech company dedicated to harnessing physiological protein homeostasis to degrade the most difficult to ligand/drug proteins. Before joining Proteovant, Zhihua was VP Head of Chemistry (2013-2021) at Agios Pharmaceuticals and Sr. Sci. Dir./Sr. Dir. of drug discovery in various therapeutics areas at Janssen Pharmaceutical Companies of Johnson & Johnson (1993-2013). He did postdoctoral research in structural based drug designs (SBDD) & Biochemistry at UCSF and received Ph.D. in Organic Synthesis at Heidelberg University in Germany. Zhihua obtained MS/BS in Medicinal Chemistry and did medical school in China. Over the years, his teams have advanced >20 compounds into the clinical development across various therapeutic areas including oncology, metabolic diseases, immunology, women’s health, men’s health and rare genetic diseases. Zhihua has more than 300 scientific publications in peer-reviewed journals and patent literature as well as invited lectures.